CTRI/2023/07/055574招募中4 期
A Placebo-Controlled, Single-Blind Sequential Study to Evaluate the Efficacy of EB-PA on Muscle Mass & Strength in Occasional Gym Goer - NI
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Males aged not less than or equal to 18 to not more than equal to 35 years with moderate physical activity levels as per International Physical Activity Questionnaire (IPAQ-SF).
- •-Occasionally gym goer with a history of at least 1 month of training but not participating in the resistance-type activity for not less than or equal to 3 months. -Habitual non-veg eater.
- •-Body mass index (BMI) 22 to 29.9 kg per m2.
- •-Waist Circumference 94 to 102 cm.
- •-Ready to refrain from caffeinated products and intense strength/ endurance exercise for 24 hrs before the exercise lab visit.
- •-Fasting blood Glucose not more than or equal 125 mg/dl.
- •-Systolic Blood Pressure not more than or erqal to 129 mm Hg and Diastolic Blood Pressure not more than or equal to 89 mm Hg.
- •-TSH (thyroid stimulating hormone) less than or equal to 0.4 and more than or equal to 4.9 mIU/L.
排除标准
- •-Engaged in structured weight training for more than 12 months before screening.
- •-Presence of chronic disease
- •-Changes in body weight of more than 4.5 kg (10 pounds) in the past three months
- •-Individuals with uncontrolled hypertension
- •-Known cases of Type II Diabetes mellitus
- •-History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic, or neurologic disorders
- •-Individuals who have any other disease or condition or are using any medication that, in the investigator’s judgment would put them at unacceptable risk for participation in the study or may interfere with evaluations or non-compliance with treatment or visits
- •-Individuals who have been part of a clinical trial within 90 days before the screening.
- •-Individuals who have used whey or other supplements anytime in the last 3 months
- •-Individuals who have used whey or other supplements anytime in the last 3 months
研究者
相似试验
进行中（未招募）
不适用
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole. - NAEstrogen Receptor Positive Locally Advanced or Metastatic Breast CancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2008-008698-69-NLovartis Pharma Services AG705
进行中（未招募）
不适用
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole. - CRAD001Y2301Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerMedDRA version: 17.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-008698-69-SEovartis Pharma Services AG705
进行中（未招募）
不适用
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole.Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerMedDRA version: 17.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-008698-69-BEovartis Pharma Services AG705
进行中（未招募）
不适用
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole.EUCTR2008-008698-69-CZovartis Pharma Services AG705
进行中（未招募）
不适用
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole. - CRAD001Y2301Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerMedDRA version: 16.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-008698-69-ATovartis Pharma Services AG705